Girocitinib vs Soficitinib (ICP-332)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2/JAK1 · full Psoriasis pipeline
Girocitinib
Developed by Hangzhou Highlightll Pharmaceutical
NCT05772520 · Phase 2 · completed
The study was randomized, triple-blind, and placebo-controlled, but it had small dose-specific groups, including 14 participants in the placebo arm. PASI-75 is a clinical endpoint; although the reported response counts favored the 20-mg and 40-mg doses, statistical significance for the primary comparison was not reported.
No aligned efficacy figure on record for this race.
Soficitinib (ICP-332)
Developed by Beijing InnoCare Pharma Tech Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Girocitinib | Soficitinib (ICP-332) |
|---|---|---|
| PASI 75 | 35.5% vs 21.4%+14.1 vs placeboNCT057725205 other results
| —Not reported |
| PASI 90 | —Not reported | —Not reported |
| PASI 100 | —Not reported | —Not reported |
| sPGA 0/1 | —Not reported | —Not reported |
| DLQI, change | —Not reported | —Not reported |
PASI 75
- Girocitinib
- 35.5% vs 21.4%+14.1 vs placeboNCT05772520
5 other results
- 44.8% vs 21.4% NCT05772520
- 50% vs 21.4% NCT05772520
- 50% vs 25% NCT05772520
- 61.1% vs 25% NCT05772520
- 50% vs 25% NCT05772520
- Soficitinib (ICP-332)
- —Not reported
PASI 90
- Girocitinib
- —Not reported
- Soficitinib (ICP-332)
- —Not reported
PASI 100
- Girocitinib
- —Not reported
- Soficitinib (ICP-332)
- —Not reported
sPGA 0/1
- Girocitinib
- —Not reported
- Soficitinib (ICP-332)
- —Not reported
DLQI, change
- Girocitinib
- —Not reported
- Soficitinib (ICP-332)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Soficitinib (ICP-332): no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Girocitinib: 3 of 4 rows · Soficitinib (ICP-332): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Girocitinib |
|---|---|
| Dropout rate | 22.6%Cohort 1 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results20.7%Cohort 2 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 0%Cohort 3 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Discontinued due to AEs | —Cohort 1 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results—Cohort 2 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 —Cohort 3 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Serious AEs | 0%Cohort 1 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results0%Cohort 2 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 0%Cohort 3 NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Most frequent reported AEs | alanine aminotransferase increased 6.5% (placebo 7.1%) headache 6.5% (placebo 0%) leukopenia 6.5% (placebo 0%) NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more resultsalanine aminotransferase increased 10.3% (placebo 7.1%) aspartate aminotransferase increased 6.9% (placebo 0%) neutropenia 6.9% (placebo 0%) NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 nasopharyngitis 12.5% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 7.1%) alanine aminotransferase increased 0% (placebo 7.1%) NCT05772520 · Phase 2 · monotherapy · Psoriasis · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Girocitinib
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Girocitinib's landscape · Soficitinib (ICP-332)'s landscape